Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23198680 | 0.88 | CYP1A2 (0.39) | CYP1A2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL17540955 | 0.78 | SLC6A2 (0.47) | CYP1A2KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL23198539 | 0.77 | SLC6A2 (0.48) | CYP1A2KDM4ENPSR1L3MBTL1NOTUM | |
| SCHEMBL19470792 | 0.73 | NR1H2 (0.37) | KDM4EALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL17551254 | 0.73 | NR1H2 (0.37) | KDM4EALDH1A1HPGDKMT2ANPSR1 | |
| SCHEMBL19991143 | 0.71 | CYP1A2 (0.39) | CYP1A2KDM4EALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL29110072 | 0.70 | KDM4E (0.42) | CYP1A2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL30685094 | 0.70 | KDM4E (0.42) | CYP1A2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL19998994 | 0.69 | CASP3 (0.38) | CYP1A2KDM4EALDH1A1HPGDNOTUM | |
| SCHEMBL18137652 | 0.68 | GLP1R (0.50) | CYP1A2ALDH1A1KMT2ANPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3185865-B1 | TETRAHYDRONAPTHTYRIDINE DERIVATIVES AS MGLUR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE. | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. | 2018-09-11 | — | — | US | disclosed |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3185865-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016032921-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | GRIN2A, GRIN2C, GRIN2B | CYP1A2 1051/4885KDM4E 1901/4885ALDH1A1 4527/4885 |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | GRIN2A, GRIN2C, GRIN2B | CYP1A2 1051/4885KDM4E 1901/4885ALDH1A1 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.